The Discounted Cash Flow (DCF) valuation of Y-mAbs Therapeutics, Inc (YMAB) is (40.87) USD. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on DCF is -574.6%.
Based on the latest price of 8.61 USD and our DCF valuation, Y-mAbs Therapeutics, Inc (YMAB) is a sell. selling YMAB stocks now will result in a potential gain of 574.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.5% - 6.9% | 6.2% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (181.27) - (23.10) | (40.87) |
| Upside | -2205.4% - -368.3% | -574.6% |